According to China's national customs statistics data analysis, pharmaceutical raw materials in China in 2006 (excluding agricultural chemicals and drugs API) import and export amounted to $ 10.346 billion. Among them, exports amounted to $ 7.482 billion, an increase of 22%; imports amounted to $ 2.864 billion, an increase of 5.59%. There is no doubt that China's pharmaceutical raw materials in the international market growth, more and more significant role and importance.
Chinese exports of bulk drugs in 2006 showed six major characteristics: the steady growth of chemical raw materials, natural medicine extracts accelerated the pace of growth; Chinese bulk drugs major trading areas in Asia, Europe and North America, Latin America into the fast growing trade area; developed State procurement of raw material medicine is China the country, but also export destination countries, in recent years stepped up to the market development in developing countries; China's API continues to antibiotics, organic acids, vitamins, amino acids, anti-inflammatory drugs these five categories based; prevailing export production enterprises, the role of trading companies in transition; more importantly, the Chinese API industry advantage and disadvantage is changing, no longer made low-cost advantages, environmental protection efforts, possession of an impact on intellectual property rights bulk drug industry, the biggest bottleneck. APIs many product categories, plus the chemical intermediates and precursors as drugs, a much larger number, classification is very complicated. According to their application and to divide compounds, antibiotics, organic acids, vitamins, amino acids, anti-inflammatory drugs these five categories is China's largest export of bulk drugs.
In 2006, insulin, amino acids, blood products, plant extracts, pharmaceutical intermediates alcohols increase the proportion of exports in 2005 exceeded 50%. In the applications, in addition to treatment, the nutritional supplements, feed additives, food supplements like a hot export products. Extracts of natural substances, such as export gains rainbow three ingredients (chemical raw materials intermediates, bio-chemical and biological drugs, natural medicine extracts) of exports, chemical intermediates, remains the most powerful advantages, the total number and amount take the absolute amount of weight. It is worth mentioning that extract natural medicine exports growth rate of 51.92% is the highest growth category of products. China has the advantage of natural drug development, therefore, natural products in the international market, China's growth potential is very considerable. On the import side, chemical intermediates, essentially flat with last year, biochemical class, extract class and import volume grew 21%, respectively, and 14.7%.
Trade zone in Latin America a fast-growing Chinese bulk drugs major trading areas in Asia, Europe and North America, Resveratrol these three regions accounted for 90% of the total import and export trade more. However, China and Latin America (South and Central America) trade from the fastest growing in 2006, respectively 48.67% and 47.16%. This region is mainly developing countries, barriers to entry are relatively lower European countries, therefore, the future of this region is China's API exports favorable area. API China and the world 183 countries and regions trade, export trade mainly arisen in North America, Europe and Asian countries, Japan and India. The two highest imports are Japan and the United States; exports were highest in the United States and India, China's API exports in India grew 41.57%, exports to the U.S. increased by 9.24%. Developing markets to be developed in the Chinese API intermediates export trade amounted million or more countries, Israel, Colombia, Nigeria, United Arab Emirates, exports to 10 countries over 50% growth year on year. Most of the 10 countries of the developing countries in Asia and the Americas. Among them, China's raw material drugs in Nigeria, Africa's largest export destination API, export growth rate of nearly 90% last year. Mainland China, Hong Kong is one of important export channel, but the export volume in 2006 declined by 32%. This shows that diversity has become the domestic export channels, resulting through the reduction in the amount of Hong Kong's entrepot trade. Japan, Canada, China's main export destination, bulk drugs, but in 2006 China's exports of bulk drugs intermediates between the total decreased by 5% and 3%.
Export production enterprises involved in the national mainstream in 2006 the export of pharmaceutical raw materials there are more than 5,000 organizations, including the annual exports of more than $ 10 million in more than 150. Leader in exports in order to operate large production companies export the majority, right after the opening of trade show producers have a stronger ability to export bulk raw materials, especially in the international drug trade, from manufacturing enterprises advantage in the export business was stronger trading company. Manufacturing enterprises in international trade opportunities for more and more, the initiative to open up export channels more. Changing the role of trading companies, its international market development and services so it is more important. Perhaps in the future only take the trading companies and manufacturers joint management mode can play to their strengths. Changes in domestic and international strengths and weaknesses of the industrial structure changes, policy-oriented development with the Chinese API industry is directly related to, and influence the future development trend of bulk drug industry. Some of the unique advantages of China, is now gradually fade, even as constraints.
Achievements in the global industrial chain transfer the bulk of China's Basic API increased sales in international markets, even in short supply, such as penicillin, antipyretic analgesics, water-soluble vitamins. This brings opportunities to China, a group to rely on large scale API profit enterprises have become the beneficiaries of the same time, extend the product chain, increasing value-added downstream products of these enterprises to become the next step of profit growth. Contract custom production increases for those who managed, innovative high-tech small and medium enterprises with high profitability and long-term stability of the order. China's domestic pharmaceutical industry, competition is bound to promote the goal of domestic enterprises to turn to the international market, thus becoming the company to accelerate the driving force of the international market. As a result, led to the introduction of cGMP enterprise management, Chia seed to accelerate the pace of the international drug certification and authentication. According to incomplete statistics, in 2006 China's pharmaceutical enterprises in the EU, the U.S. registration and registration of DMF increased the number of documents a dozen, its effective totals to the 121 and 345. In the past, analysis of China's dominant position in the pharmaceutical always think of low cost, low environmental requirements, but with the increase of domestic environmental protection efforts, the RMB currency appreciation, corporate management costs, improve the quality of personnel, these advantages gradually appears to be negligible. Especially in the international high-end market and high-tech, these even become a disadvantage. The future, the implementation of environmental protection, intellectual property has become China's API industry most worthy of study, only the rising environmental protection measures, protection of intellectual property and the ability to really establish the use of Chinese medicine raw materials in the global dominance of the field of medicine. Pharmaceutical raw materials China's total exports in 2006 grew 22%, but the former advantage is gradually diluted, the intensity of environmental protection, intellectual property rights affect the share of bulk drugs will be the development of the industry's biggest bottleneck. Source:http://www.cospcn.com